Dimerix adds Mexican patent shield for Phase 2 kidney drug DMX-652

Mexican Patent Extends DMX-652 Protection

Dimerix Limited (ASX:DXB) has added Mexico to the protected territory for DMX-652, winning a composition of matter patent that covers the active molecule until 3 June 2041. Patent number 438406 was granted by Mexico’s Institute of Industrial Property for “N-cyanopyrrolidines with activity as USP30 inhibitors”.

That is a more meaningful form of protection than a patent limited to a particular formulation or use: composition of matter claims protect the molecule itself. Dimerix says the Mexican grant strengthens the commercialisation case for DMX-652 and complements a recently granted US composition of matter patent, adding another major pharmaceutical market to the asset’s intellectual property portfolio.

Mexico Adds a Significant Pharmaceutical Market

The company puts Mexico’s pharmaceutical market at more than US$15 billion, making it Latin America’s second-largest market after Brazil and approximately the twelfth-largest worldwide. The filing does not disclose any Mexican commercial partner, launch plan or revenue forecast, so the immediate significance is strategic rather than financial.

For Dimerix, the patent arrives as DMX-652 moves towards a Phase 2 trial in acute kidney injury associated with cardiac surgery. The company says the acquired asset has an open US Investigational New Drug application, a Phase 2 protocol cleared to proceed by the US Food and Drug Administration, pharmaceutical-grade drug product and manufacturing methodology in place.

Phase 2 Trial Remains the Key Test

DMX-652 is an oral, once-daily selective inhibitor of USP30, a mitochondrial enzyme involved in the removal of damaged mitochondria. Dimerix is developing it to support mitophagy, the natural process by which cells clear damaged mitochondria, and to investigate whether that mechanism can prevent kidney injury and preserve renal function.

Acute kidney injury can develop rapidly after high-risk events including cardiac surgery and sepsis. Dimerix says there are currently no approved therapies for AKI, but the Mexican patent does not alter that clinical reality or provide evidence of efficacy. The next material question is whether the planned Phase 2 study can translate DMX-652’s proposed mechanism into a measurable clinical benefit.